A Proof-of-Concept for Explainable Disease Diagnosis Using Large Language Models and Answer Set Programming

Accurate disease prediction is vital for timely intervention, effective treatment, and reducing medical complications. While symbolic AI has been applied in healthcare, its adoption remains limited due to the effort required for constructing high-quality knowledge bases. This work introduces McCoy, a framework that combines Large Language Models (LLMs) with Answer Set Programming (ASP) to overcome this barrier. McCoy orchestrates an LLM to translate medical literature into ASP code, combines it with patient data, and processes it using an ASP solver to arrive at the final diagnosis. This integration yields a robust, interpretable prediction framework that leverages the strengths of both paradigms. Preliminary results show McCoy has strong performance on small-scale disease diagnosis tasks.

K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction

Drug discovery is a complex and time-intensive process that requires identifying and validating new therapeutic candidates. Computational approaches using large-scale biomedical knowledge graphs (KGs) offer a promising solution to accelerate this process. However, extracting meaningful insights from large-scale KGs remains challenging due to the complexity of graph traversal. Existing subgraph-based methods are tailored to graph neural networks (GNNs), making them incompatible with other models, such as large language models (LLMs). We introduce K-Paths, a retrieval framework that extracts structured, diverse, and biologically meaningful paths from KGs. Integrating these paths enables LLMs and GNNs to effectively predict unobserved drug-drug and drug-disease interactions. Unlike traditional path-ranking approaches, K-Paths retrieves and transforms paths into a structured format that LLMs can directly process, facilitating explainable reasoning. K-Paths employs a diversity-aware adaptation of Yen's algorithm to retrieve the K shortest loopless paths between entities in an interaction query, prioritizing biologically relevant and diverse relationships. Our experiments on benchmark datasets show that K-Paths improves the zero-shot performance of Llama 8.1B's F1-score by 12.45 points on drug repurposing and 13.42 points on interaction severity prediction. We also show that Llama 70B achieves F1-score gains of 6.18 and 8.46 points, respectively. K-Paths also improves the supervised training efficiency of EmerGNN, a state-of-the-art GNN, by reducing KG size by 90% while maintaining strong predictive performance. Beyond its scalability and efficiency, K-Paths uniquely bridges the gap between KGs and LLMs, providing explainable rationales for predicted interactions. These capabilities show that K-Paths is a valuable tool for efficient data-driven drug discovery.